PURPOSE: This study assesses the ability of multidrug resistance (MDR)-associated gene expression patterns to predict survival in patients with newly diagnosed carcinoma of the ovary. The scope of this research differs substantially from that of previous reports, as a very large set of genes was evaluated whose expression has been shown to affect response to chemotherapy. EXPERIMENTAL DESIGN: We applied a customized TaqMan low density array, a highly sensitive and specific assay, to study the expression profiles of 380 MDR-linked genes in 80 tumor specimens collected at initial surgery to debulk primary serous carcinoma. The RNA expression profiles of these drug resistance genes were correlated with clinical outcomes. RESULTS: Leave-one-out cross-validation was used to estimate the ability of MDR gene expression to predict survival. Although gene expression alone does not predict overall survival (OS; P = 0.06), four covariates (age, stage, CA125 level, and surgical debulking) do (P = 0.03). When gene expression was added to the covariates, we found an 11-gene signature that provides a major improvement in OS prediction (log-rank statistic P < 0.003). The predictive power of this 11-gene signature was confirmed by dividing high- and low-risk patient groups, as defined by their clinical covariates, into four specific risk groups on the basis of expression levels. CONCLUSION: This study reveals an 11-gene signature that allows a more precise prognosis for patients with serous cancer of the ovary treated with carboplatin- and paclitaxel-based therapy. These 11 new targets offer opportunities for new therapies to improve clinical outcome in ovarian cancer.
PURPOSE: This study assesses the ability of multidrug resistance (MDR)-associated gene expression patterns to predict survival in patients with newly diagnosed carcinoma of the ovary. The scope of this research differs substantially from that of previous reports, as a very large set of genes was evaluated whose expression has been shown to affect response to chemotherapy. EXPERIMENTAL DESIGN: We applied a customized TaqMan low density array, a highly sensitive and specific assay, to study the expression profiles of 380 MDR-linked genes in 80 tumor specimens collected at initial surgery to debulk primary serous carcinoma. The RNA expression profiles of these drug resistance genes were correlated with clinical outcomes. RESULTS: Leave-one-out cross-validation was used to estimate the ability of MDR gene expression to predict survival. Although gene expression alone does not predict overall survival (OS; P = 0.06), four covariates (age, stage, CA125 level, and surgical debulking) do (P = 0.03). When gene expression was added to the covariates, we found an 11-gene signature that provides a major improvement in OS prediction (log-rank statistic P < 0.003). The predictive power of this 11-gene signature was confirmed by dividing high- and low-risk patient groups, as defined by their clinical covariates, into four specific risk groups on the basis of expression levels. CONCLUSION: This study reveals an 11-gene signature that allows a more precise prognosis for patients with serous cancer of the ovary treated with carboplatin- and paclitaxel-based therapy. These 11 new targets offer opportunities for new therapies to improve clinical outcome in ovarian cancer.
Authors: Dimitrios Spentzos; Douglas A Levine; Marco F Ramoni; Marie Joseph; Xuesong Gu; Jeff Boyd; Towia A Libermann; Stephen A Cannistra Journal: J Clin Oncol Date: 2004-10-25 Impact factor: 44.544
Authors: D A Porter; I E Krop; S Nasser; D Sgroi; C M Kaelin; J R Marks; G Riggins; K Polyak Journal: Cancer Res Date: 2001-08-01 Impact factor: 12.701
Authors: Alexandra Giatromanolaki; Michael I Koukourakis; Heidi M Sowter; Efthimios Sivridis; Spencer Gibson; Kevin C Gatter; Adrian L Harris Journal: Clin Cancer Res Date: 2004-08-15 Impact factor: 12.531
Authors: Vikki M Abrahams; Shawn L Straszewski; Marijke Kamsteeg; Bozena Hanczaruk; Peter E Schwartz; Thomas J Rutherford; Gil Mor Journal: Cancer Res Date: 2003-09-01 Impact factor: 12.701
Authors: Jashodeep Datta; Anna Bianchi; Iago De Castro Silva; Nilesh U Deshpande; Long Long Cao; Siddharth Mehra; Samara Singh; Christine Rafie; Xiaodian Sun; Xi Chen; Xizi Dai; Antonio Colaprico; Prateek Sharma; Austin R Dosch; Asha Pillai; Peter J Hosein; Nagaraj S Nagathihalli; Krishna V Komanduri; Julie M Wilson; Yuguang Ban; Nipun B Merchant Journal: Oncogene Date: 2022-06-14 Impact factor: 8.756
Authors: Matthew D Hall; Travis S Marshall; Alexandra D T Kwit; Lisa M Miller Jenkins; Andrés E Dulcey; James P Madigan; Kristen M Pluchino; Andrew S Goldsborough; Kyle R Brimacombe; Gary L Griffiths; Michael M Gottesman Journal: J Biol Chem Date: 2014-06-14 Impact factor: 5.157
Authors: Markus Riester; Wei Wei; Levi Waldron; Aedin C Culhane; Lorenzo Trippa; Esther Oliva; Sung-Hoon Kim; Franziska Michor; Curtis Huttenhower; Giovanni Parmigiani; Michael J Birrer Journal: J Natl Cancer Inst Date: 2014-04-03 Impact factor: 13.506
Authors: Benjamin Frederick Ganzfried; Markus Riester; Benjamin Haibe-Kains; Thomas Risch; Svitlana Tyekucheva; Ina Jazic; Xin Victoria Wang; Mahnaz Ahmadifar; Michael J Birrer; Giovanni Parmigiani; Curtis Huttenhower; Levi Waldron Journal: Database (Oxford) Date: 2013-04-02 Impact factor: 3.451